NeuBase Therapeutics, Inc

(NASDAQ:NBSE)

Latest On NeuBase Therapeutics, Inc (NBSE):

Date/Time Type Description Signal Details
2023-05-11 22:40 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02N/A
2023-02-15 00:46 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.13 misses by $0.02N/A
2022-12-22 01:26 ESTNewsNeuBase Therapeutics GAAP EPS of -$1.04 beats by $0.04N/A
2022-10-21 10:11 ESTNewsNeuBase stock rises on gene editing research collaborationN/A
2022-10-14 20:22 ESTNewsNeuBase Therapeutics announces restructuring, to cut 60% of workforceN/A
2022-08-11 13:00 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04N/A
2022-06-29 20:38 ESTNewsNeuBase Therapeutics promotes Dr. William Mann to President and COON/A
2022-05-12 21:21 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.30 misses by $0.06N/A
2022-02-11 06:41 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.24N/A
2022-01-10 23:06 ESTNewsNeuBase Therapeutics names Phathom's Todd Branning as new CFON/A
2021-12-27 17:13 ESTNewsNeuBase Therapeutics reports FY resultsN/A
2021-10-25 22:31 ESTNewsWarning: NBSE is at high risk of performing badlyN/A
2021-08-12 21:20 ESTNewsNeuBase Therapeutics EPS misses by $0.07N/A
2021-04-22 19:23 ESTNewsNeuBase Therapeutics stock continues slumping, prices $40M public offeringN/A
2021-04-21 22:21 ESTNewsNeuBase Therapeutics slumps on launching stock offeringN/A
2021-03-18 23:20 ESTNewsNeubase Therapeutics (NBSE) Investor Presentation - SlideshowN/A
2021-03-16 21:30 ESTAnalyst RatingThe Analyst Target Price has increased from $16.8 to $17.Buy
2021-02-19 04:10 ESTAnalyst RatingThe Analyst Target Price has increased from $16.17 to $16.8.Buy
2021-02-15 12:04 ESTAnalyst RatingThe Analyst Target Price has increased from $15.67 to $16.17.Buy
2021-02-12 12:02 ESTEarnings EstimateAn EPS average of -$0.24 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-12 04:22 ESTNewsNeuBase Therapeutics EPS beats by $0.05N/A
2021-02-12 04:11 ESTFinancialsCompany financials have been released.Neutral
2021-01-28 10:43 ESTNewsNeuBase snaps gene modulating technology from Vera TherapeuticsN/A
2021-01-21 12:10 ESTNewsAssured Guaranty falls as Greenlight reveals short in new investor letterN/A
2021-01-06 16:16 ESTFinancialsCompany financials have been released.Neutral
2020-12-25 08:33 ESTAnalyst RatingThe Analyst Target Price has increased from $15.2 to $15.67.Buy
2020-12-25 00:39 ESTFinancialsCompany financials have been released.Neutral
2020-12-24 16:24 ESTEarnings EstimateAn EPS average of -$1.19 is estimated for the 2022 year.Sell
2020-12-24 16:24 ESTEarnings EstimateAn EPS average of -$0.25 is estimated for the quarter ending on March 31, 2021.Sell
2020-12-24 16:24 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.67 to $15.2.Neutral
2020-12-23 16:39 ESTNewsNeuBase Therapeutics EPS in-lineN/A
2020-12-16 09:24 ESTNewsNeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophyN/A
2020-11-26 20:56 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:34 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:30 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-31 17:08 ESTFinancialsCompany financials have been released.Neutral
2020-08-29 09:06 ESTFinancialsCompany financials have been released.Neutral
2020-08-25 17:22 ESTFinancialsCompany financials have been released.Neutral
2020-08-22 05:10 ESTFinancialsCompany financials have been released.Neutral
2020-08-17 21:25 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 17:17 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:33 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 05:16 ESTEarnings EstimateAn EPS average of -$0.24 is estimated for the quarter ending on December 31, 2020.Sell
2020-08-13 23:18 ESTNewsNeuBase Therapeutics reports FQ3 resultsN/A
2020-08-06 21:24 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 02:24 ESTNewsNeuBase Therapeutics appoints industry veteran as COON/A

About NeuBase Therapeutics, Inc (NBSE):

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Quotes by TradingView

See Advanced Chart

General

  • Name NeuBase Therapeutics, Inc
  • Symbol NBSE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 15
  • Fiscal Year EndSeptember
  • IPO Date2007-05-01
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.neubasetherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 7.53
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.88
  • Next Year EPS Estimate -$1.23
  • Next Quarter EPS Estimate -$0.24
  • Return on Assets -55%
  • Return on Equity -95%
  • Earnings Per Share -$0.12
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 198.87 million
  • Analyst Target Price $17
  • Book Value Per Share $0.59
View More

Share Statistics

  • Shares Outstanding 23.18 million
  • Shares Float 17.6 million
  • % Held by Insiders 1707%
  • % Held by Institutions 31.94%
  • Shares Short 881734
  • Shares Short Prior Month 805036
  • Short Ratio 2.72
  • Short % of Float 4%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • 52 Week High $12.89
  • 52 Week Low $4.52
  • 50 Day Moving Average 10
  • 200 Day Moving Average 8.57
View More

Dividends

  • Dividend Date 2019-02-04
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

NeuBase Therapeutics, Inc (NBSE) Dividend Calendar:

NBSE's last dividend payment was made to shareholders on February 4, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

NeuBase Therapeutics, Inc (NBSE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.18-$0.2423.4%
2020-09-302020-12-23$N/A-$0.20-$0.20-0.86%
2020-06-302020-08-13$N/A-$0.18-$0.2320.6%
2020-03-312020-05-14$N/A-$0.26-$0.22-16.85%
2019-12-312020-03-26$N/A-$0.26-$0.3628.43%
2019-09-302019-09-30$N/A-$2.14-$0.28-664.29%
2019-06-302019-08-14$N/A-$0.40
2019-03-312019-05-15$N/A-$0.40
2018-12-312019-01-03$N/A-$0.32
2018-09-302018-12-15-$2.25
2018-06-302018-08-14-$0.19
2018-03-312018-05-15-$1.00-$1.4028.57%
2017-12-312018-02-14-$1.40-$1.400%
2017-09-302017-12-15-$1.60-$1.600%
2017-06-302017-08-08-$1.45
2017-03-312017-05-11-$0.21-$0.3030%
2016-12-312017-02-14-$0.21-$0.19-10.53%
2016-09-302016-12-22$N/A-$0.21-$0.2412.5%
2016-06-302016-08-09$N/A-$0.24-$0.2711.11%
2016-03-312016-05-10$N/A-$0.17-$0.185.56%
2015-12-312016-02-09$N/A-$0.20-$0.2416.67%
2015-09-302015-12-10$N/A-$0.13-$0.1931.58%
2015-06-302015-08-06$N/A-$0.11-$0.1838.89%
2015-03-312015-05-11$N/A-$0.12-$0.1833.33%
2014-12-312015-02-09$N/A-$0.18-$0.2010%
2014-09-302014-12-22$N/A-$0.12-$0.10-20%
2014-06-302014-08-18$N/A-$1.80-$2.0010%
2014-03-312014-05-13$N/A-$2.00-$2.4016.67%
2013-12-312014-02-14$N/A-$2.00-$2.000%
2013-09-302013-12-27-$1.40-$1.400%
2013-06-302013-08-13-$1.40-$0.80-75%
2013-03-312013-05-14-$0.60-$1.2050%
2012-12-312013-01-09-$1.80-$0.60-200%
2012-06-302012-08-29-$0.66
2012-03-312012-05-30-$2.04
2011-12-312011-12-31$0.40
2011-09-302011-09-30-$2.11
2011-06-302011-06-30-$4.74
2011-03-312011-03-31-$0.24
2010-12-312010-12-31-$0.76
2010-09-302010-09-30$6.53
2010-06-302010-06-30-$0.30
2010-03-312010-03-31-$5.24
2009-12-312009-12-31-$0.38
2009-09-302009-09-30-$0.30
2009-06-302009-06-30-$0.49
2009-03-312009-03-31-$1.06
2008-12-312008-12-31-$0.16
2008-09-302008-09-30-$0.67
2008-06-302008-06-30$0.02
2008-03-312008-03-31-$0.22
2007-12-312007-12-31$0.75
2007-09-302007-09-30-$0.46
2007-06-302007-06-30-$7.68
2007-03-312007-03-31-$51.37
2006-12-312006-12-31$0.60
2006-09-302006-09-30-$0.38
2006-06-302006-06-30$1.92
2006-03-312006-03-31$0.90
2005-12-312005-12-31-$0.83
2005-09-302005-09-30$1.70
2005-06-302005-06-30-$0.62
2005-03-312005-03-31$1.30
2004-12-312004-12-31$4.80
2004-09-302004-09-30$1.01
2004-06-302004-06-30$1.89

NeuBase Therapeutics, Inc (NBSE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development 2.02 million 2.61 million N/A 1.49 million 1.62 million
Income Before Tax -4.07 million -4.7 million N/A -3.8 million -4.38 million
Selling General Administrative 2.64 million 2.5 million N/A 2.33 million 2.74 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -4.07 million -4.65 million N/A -3.77 million -4.33 million
Operating Income -4.66 million -5.11 million N/A -3.82 million -4.36 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A 411394 N/A 25849 -22898
Net Income From Continuing Operations -4.07 million -4.7 million N/A -3.8 million -4.38 million
Net Income Applicable to Common Shares -4.07 million N/A -3.8 million -3.8 million N/A
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -353905 N/A -200999 -93516 -93516
Change to Liabilities N/A -353595 -353595 N/A 297552
Total Cash Flow from Investing Activities N/A -200999 -200999 N/A -93516
Net Borrowings N/A -45006 -45006 N/A -49493
Total Cash Flow from Financial Activities -10837 N/A 33.24 million -49493 -49493
Change to Operating Activities N/A -360126 -360126 N/A 852959
Change in Cash -3.93 million N/A 30.15 million -1.96 million -1.96 million
Total Cash from Operating Activities -3.57 million -2.89 million -2.89 million -1.82 million -1.82 million
Depreciation 49748 N/A 31215 49754 49754
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A 1.6 million 1.6 million N/A 1.36 million
Capital Expenditures 353905 N/A 200999 93516 93516
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities 2.24 million 3.15 million N/A N/A 3.73 million
Total Stockholder Equity 28.52 million 31.29 million N/A N/A 3.99 million
Other Current Liabilities 320039 950151 N/A N/A 1.12 million
Total Assets 30.76 million 34.44 million N/A N/A 7.72 million
Common Stock 2317 N/A 2312 N/A N/A
Other Current Assets 841389 N/A N/A 2312 N/A
Retained Earnings -47.63 million -43.56 million -39.68 million -39.68 million -35.88 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A 193666 193666 N/A
Cash 27.98 million 31.99 million N/A N/A 5.77 million
Total Current Liabilities 2.24 million 3.15 million N/A N/A 3.73 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 1.29 million N/A 705798 705798 N/A
Total Current Assets 28.82 million 32.81 million N/A N/A 6.47 million
Long Term Investments 298145 323557 N/A N/A 469067
Net Tangible Assets 28.52 million N/A 34.68 million 34.68 million N/A
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.92 million 1.51 million N/A N/A 1.66 million

NeuBase Therapeutics, Inc (NBSE) Chart:

NeuBase Therapeutics, Inc (NBSE) News:

Below you will find a list of latest news for NeuBase Therapeutics, Inc (NBSE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

NeuBase Therapeutics, Inc (NBSE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2032-10-2150PUT 0TRUE00

Latest NBSE Trades:

Date Shares Price
Jun 13, 2022 3:43 PM EST100$0.9323
Jun 13, 2022 3:43 PM EST100$0.9188
Jun 13, 2022 3:43 PM EST100$0.9127
Jun 13, 2022 3:43 PM EST100$0.9127

NeuBase Therapeutics, Inc (NBSE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1173281/000110465920079797/0001104659-20-079797-index.htm
2019-04-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019006762/0000000000-19-006762-index.htm
2019-05-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019007949/0000000000-19-007949-index.htm
2019-05-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019008674/0000000000-19-008674-index.htm
2019-09-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019013774/0000000000-19-013774-index.htm
2019-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000092963819000683/0000929638-19-000683-index.htm
2019-12-31NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1173281/000110465919077303/0001104659-19-077303-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920002674/0001104659-20-002674-index.htm
2020-01-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1173281/000110465920003043/0001104659-20-003043-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920020287/0001104659-20-020287-index.htm
2020-02-14NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1173281/000110465920022019/0001104659-20-022019-index.htm
2020-02-188-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920022491/0001104659-20-022491-index.htm
2020-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920023939/0001104659-20-023939-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920038784/0001104659-20-038784-index.htm
2020-03-268-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920038899/0001104659-20-038899-index.htm
2020-03-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920038903/0001104659-20-038903-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920040873/0001104659-20-040873-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920043210/0001104659-20-043210-index.htm
2020-04-038-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920043215/0001104659-20-043215-index.htm
2020-04-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920051617/0001104659-20-051617-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920052567/0001104659-20-052567-index.htm
2020-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920053403/0001104659-20-053403-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920054436/0001104659-20-054436-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920055957/0001104659-20-055957-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920056066/0001104659-20-056066-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920056110/0001104659-20-056110-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920056160/0001104659-20-056160-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920061594/0001104659-20-061594-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920061711/0001104659-20-061711-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920065897/0001104659-20-065897-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920071404/0001104659-20-071404-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920071857/0001104659-20-071857-index.htm
2020-07-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920079774/0001104659-20-079774-index.htm
2020-07-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1173281/000110465920079797/0001104659-20-079797-index.htm
2020-07-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920087039/0001104659-20-087039-index.htm
2020-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920087336/0001104659-20-087336-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920087347/0001104659-20-087347-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920094366/0001104659-20-094366-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920094671/0001104659-20-094671-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920094763/0001104659-20-094763-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104478/0001104659-20-104478-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104488/0001104659-20-104488-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104489/0001104659-20-104489-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104491/0001104659-20-104491-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104493/0001104659-20-104493-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920112440/0001104659-20-112440-index.htm
2018-01-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000058/0001387131-18-000058-index.htm
2018-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000666/0001387131-18-000666-index.htm
2018-02-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713118000667/0001387131-18-000667-index.htm
2018-02-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000710/0001387131-18-000710-index.htm
2018-02-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000769/0001387131-18-000769-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118002194/0001387131-18-002194-index.htm
2018-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713118002211/0001387131-18-002211-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004003/0001387131-18-004003-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713118004016/0001387131-18-004016-index.htm
2018-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004183/0001387131-18-004183-index.htm
2018-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004298/0001387131-18-004298-index.htm
2018-09-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004559/0001387131-18-004559-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118005225/0001387131-18-005225-index.htm
2018-12-07PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118006691/0001387131-18-006691-index.htm
2018-12-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118006826/0001387131-18-006826-index.htm
2018-12-31NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1173281/000138713118007126/0001387131-18-007126-index.htm
2019-01-0310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1173281/000138713119000051/0001387131-19-000051-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000062/0001387131-19-000062-index.htm
2019-01-03425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000063/0001387131-19-000063-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000419/0001387131-19-000419-index.htm
2019-01-23425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000420/0001387131-19-000420-index.htm
2019-02-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119001277/0001387131-19-001277-index.htm
2019-02-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001282/0001387131-19-001282-index.htm
2019-02-15425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001283/0001387131-19-001283-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001453/0001387131-19-001453-index.htm
2019-03-08S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001802/0001387131-19-001802-index.htm
2019-04-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119002689/0001387131-19-002689-index.htm
2019-04-16S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119002690/0001387131-19-002690-index.htm
2019-05-07S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003388/0001387131-19-003388-index.htm
2019-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003390/0001387131-19-003390-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003726/0001387131-19-003726-index.htm
2019-05-15425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003727/0001387131-19-003727-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119003729/0001387131-19-003729-index.htm
2019-05-22S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003888/0001387131-19-003888-index.htm
2019-05-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003889/0001387131-19-003889-index.htm
2019-06-03S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004175/0001387131-19-004175-index.htm
2019-06-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004220/0001387131-19-004220-index.htm
2019-06-06424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119004248/0001387131-19-004248-index.htm
2019-07-02425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004795/0001387131-19-004795-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004832/0001387131-19-004832-index.htm
2019-07-03425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004833/0001387131-19-004833-index.htm
2019-07-08425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004892/0001387131-19-004892-index.htm
2019-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004960/0001387131-19-004960-index.htm
2019-07-10425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004961/0001387131-19-004961-index.htm
2019-07-118-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004992/0001387131-19-004992-index.htm
2019-07-11425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004993/0001387131-19-004993-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005021/0001387131-19-005021-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005123/0001387131-19-005123-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005124/0001387131-19-005124-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005125/0001387131-19-005125-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005126/0001387131-19-005126-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005127/0001387131-19-005127-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005128/0001387131-19-005128-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005129/0001387131-19-005129-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005130/0001387131-19-005130-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005131/0001387131-19-005131-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005132/0001387131-19-005132-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005133/0001387131-19-005133-index.htm
2019-07-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005158/0001387131-19-005158-index.htm
2019-07-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005251/0001387131-19-005251-index.htm
2019-07-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005253/0001387131-19-005253-index.htm
2019-07-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005254/0001387131-19-005254-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119006142/0001387131-19-006142-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119006165/0001387131-19-006165-index.htm
2019-08-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119006228/0001387131-19-006228-index.htm
2019-09-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1173281/000138713119006938/0001387131-19-006938-index.htm
2019-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119007028/0001387131-19-007028-index.htm
2019-09-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119007087/0001387131-19-007087-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119007089/0001387131-19-007089-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119007419/0001387131-19-007419-index.htm
2020-05-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713120004350/0001387131-20-004350-index.htm
2019-07-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000153538419000009/0001535384-19-000009-index.htm
2019-08-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000178640619000001/0001786406-19-000001-index.htm
2019-06-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1173281/999999999519001291/9999999995-19-001291-index.htm
2019-09-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1173281/999999999519002155/9999999995-19-002155-index.htm
2019-06-07CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1173281/999999999719005367/9999999997-19-005367-index.htm

NeuBase Therapeutics, Inc (NBSE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of NeuBase Therapeutics, Inc (NBSE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1707%
Institutional Ownership: 3194%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-30Dietrich A StephanPresident and CEOBuy10,000.006.0060,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920056160/0001104659-20-056160-index.htm
2020-04-30DOV A MD GOLDSTEINDirectorBuy10,000.006.0060,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920056110/0001104659-20-056110-index.htm
2020-05-21Dietrich A StephanPresident and CEOBuy1,250.008.0910,111.0011,250.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920065897/0001104659-20-065897-index.htm
2020-04-30Samuel BackenrothCFO, Treasurer & SecretaryBuy1,000.006.006,000.0011,630.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920056066/0001104659-20-056066-index.htm
2020-06-09Dietrich A StephanPresident and CEOBuy1,275.007.739,860.7212,525.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920071857/0001104659-20-071857-index.htm
2019-07-12ERIC I RICHMANDirectorBuy25,247.0025,247.00https://www.sec.gov/Archives/edgar/data/1173281/000138713119005131/0001387131-19-005131-index.htm
2019-07-12Dietrich A StephanPresident and CEOBuy2,547,639.002,547,639.00https://www.sec.gov/Archives/edgar/data/1173281/000138713119005132/0001387131-19-005132-index.htm
2020-04-30ERIC I RICHMANDirectorBuy2,500.006.0015,000.0027,747.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920055957/0001104659-20-055957-index.htm
2020-04-30ERIC I RICHMANDirectorBuy8,333.006.0049,998.0036,080.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920055957/0001104659-20-055957-index.htm